• A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

  NCT05066646

  Unknown statusInterventionalPhase 1Phase 2Updated Nov 23, 2021
• A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

  NCT05698303

  Unknown statusInterventionalPhase 1Updated Jan 26, 2023
• Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

  NCT04194931

  Unknown statusInterventionalPhase 1Updated Dec 11, 2019
• BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

  NCT03093168

  Unknown statusInterventionalPhase 1Updated Feb 27, 2019
• A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

  NCT05712083

  Unknown statusInterventionalPhase 2Updated Feb 21, 2023
• A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

  NCT04670055

  Not yet recruitingInterventionalEarly Phase 1Updated Dec 17, 2020

ClinicalTrials.gov ID

NCT05181501

Lead Sponsor

Nanjing IASO Biotechnology Co., Ltd.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

20Estimated

Last Update Posted

Jan 6, 2022Actual

Start Date

Apr 2022Estimated

Primary Completion Date

Apr 2024Estimated

Completion Date

Apr 2039Estimated

Official Title

A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)

Brief Summary

This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.

Detailed Description

Before enrollment, subjects will receive chemotherapy regimen of either Bortezomib-Lenalidomide-Dexamethasone (VRD), Bortezomib-Cyclophosphamide-Dexamethasone (PCD) or Bortezomib-Adriamycin-Dexamethasone (PAD) as induction therapy for 3 cycles. Evaluation will be made after 2 cycles of chemotherapy. If the subject is not intended to have stem cell transplantation or unsuitable for autologous hematopoietic stem cell transplantation (ASCT) as judged by the investigator, he/she will receive the 3rd cycle of chemotherapy. If the subject meets the inclusion criteria, he/she will be enrolled in the study.

Peripheral blood mononuclear cell (PBMC) will be collected to manufacture CT103A. After PBMC collection, the subject will receive another cycle of chemotherapy and evaluated. Lymphodepletion with fludarabine and cyclophosphamide will be performed for three consecutive days. After 1-day rest, subjects will receive a single infusion of CT103A at 1.0 ×10^6 /kg. Subjects will be followed in the study for a minimum of 2 years after CT103A infusion. Long-term follow-up for lentiviral vector safety will be followed for up to 15 years after CT103A infusion.

• Multiple Myeloma

• Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. 18 to 70 years old, male or female;

2. Newly diagnosed as high-risk multiple myeloma:

   • Revised Multiple Myeloma International Staging System (R-ISS) stage 3;
   • Double-hit or triple-hit according to FISH test.

3. Presence of measurable lesions during screening according to any of the following criteria:

   • The proportion of primitive naive or monoclonal plasma cells ≥ 5% by bone marrow cytology, bone marrow biopsy histology or flow cytometry;
   • Serum monoclonal protein (M-protein) level: M protein ≥10 g/L for IgG type, M protein ≥5g/L for IgA, IgD, IgM, and IgE type;
   • Urine M protein level ≥200 mg/24 hours;
   • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;

4. ECOG score of 0 or 1;

5. Expected survival time ≥ 12 weeks;

6. Subjects must have appropriate organ functions and meet all the following laboratory test requirements before enrollment:

   • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (prior growth factor support is allowed, but supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥75×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test; recombinant human erythropoietin is allowed);
   • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
   • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
   • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
   • Blood oxygen saturation>91%;
   • Left ventricular ejection fraction (LVEF) ≥50%;

7. Subjects and their spouses agree to take effective tools or contraceptive measures (safe period contraception is not included) from the time the subject signs the informed consent form until one year after the CAR-T cell infusion.

Exclusion Criteria:

1. Patient who needs chronic use of immunosuppressive agents;
2. Patient with hypertension that cannot be controlled by medication;
3. Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia;
4. Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases that require drug treatment;
5. Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast;
6. Patient with a history of solid organ transplantation;
7. Patient who is suspected with or with symptoms of central nervous system invasion by plasma cell tumors;
8. Multiple myeloma patients with plasma cell leukemia;
9. Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;
10. Women who are pregnant or breastfeeding;
11. Patient with mental illness or disturbance of consciousness or central nervous system disease;
12. Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;
13. Other situations considered unsuitable by the investigator.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Nanjing IASO Biotechnology Co., Ltd.INDUSTRY

chenljb@126.com025-68306091

chenbing2004@126.com025-83106666